Loading…
VYNE Therapeutics Inc. is projected to rise to $0.7366 by 2027, a +17% move from its current price of $0.63. VYNE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $0.618 | $0.6303 | $0.6429 | +0.05% |
| Jul 13 | $0.6133 | $0.6306 | $0.6485 | +0.10% |
| Jul 14 | $0.6097 | $0.6309 | $0.6529 | +0.15% |
| Jul 15 | $0.6068 | $0.6312 | $0.6566 | +0.20% |
| Jul 16 | $0.6043 | $0.6315 | $0.66 | +0.24% |
| Jul 17 | $0.602 | $0.6318 | $0.6631 | +0.29% |
| Jul 18 | $0.60 | $0.6322 | $0.666 | +0.34% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.60 | $0.6322 | $0.666 | +0.34% |
| Week 2 | $0.5892 | $0.6343 | $0.6829 | +0.68% |
| Week 3 | $0.5815 | $0.6365 | $0.6967 | +1.03% |
| Week 4 | $0.5753 | $0.6387 | $0.7089 | +1.37% |
| Week 5 | $0.5702 | $0.6408 | $0.7202 | +1.72% |
| Week 6 | $0.5658 | $0.643 | $0.7307 | +2.07% |
| Week 7 | $0.562 | $0.6452 | $0.7408 | +2.42% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to treat chronic inflammatory and immune-mediated conditions. Its lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple inflammatory cell signaling pathways with low systemic exposure.
It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc.
in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
VYNE Therapeutics Inc. (VYNE) is a healthcare stock with a current price of $0.63 and a market capitalization of $21.03M, ranking 4861 by market cap.
The forecast table shows a bullish price path over time, with the 2026 average price at $0.63 and higher targets thereafter. Key long-range milestones include a 2030 average of $0.9064 and a 2050 average of $4.24, with max scenarios up to $1.24 (2030), $3.85 (2040), and $7.02 (2050).
A major floor 7.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.3% away) — a key level to hold.
The nearest ceiling, 9.0% above — a clean break opens room to run.
A major ceiling 13.3% above — clearing it would confirm fresh momentum.
Key VYNE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VYNE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.6596 | Sell | $0.6562 | Sell |
| MA 10 | $0.6606 | Sell | $0.6579 | Sell |
| MA 20 | $0.6522 | Sell | $0.6575 | Sell |
| MA 50 | $0.6611 | Sell | $0.6518 | Sell |
| MA 100 | $0.6344 | Sell | $0.6335 | Sell |
| MA 200 | $0.5406 | Buy | $0.6966 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.34 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -77.09 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -1.85 | Sell |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.00 | Sell |
| Awesome (5,34) | -0.00 | Sell |
| Ultimate (7,14,28) | 46.12 | Neutral |
| Momentum (10) | -0.01 | Sell |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 0.65 | Sell |
| ADX (14) | 13.15 | Neutral |
| ATR (14) | 0.01 | Info |
The 30-day picture is NEUTRAL. RSI14 stands at 40, with the 50-day simple moving average at $0.6611 and the 200-day simple moving average at $0.5406.
Near-term support is seen at $0.622 and resistance at $0.687. The stock’s 30-day range runs from $0.5532 to $0.7175, and annualized volatility is 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.554 | $0.63 | $0.8356 | 0% | Neutral | |
| $0.6014 | $0.7366 | $0.9444 | +17% | Neutral | |
| $0.6741 | $0.8418 | $1.11 | +34% | Bullish | |
| $0.6855 | $0.8699 | $1.17 | +38% | Bullish | |
| $0.7042 | $0.9064 | $1.24 | +44% | Bullish | |
| $0.835 | $1.09 | $1.52 | +73% | Bullish | |
| $0.9543 | $1.26 | $1.78 | +100% | Bullish | |
| $1.07 | $1.43 | $2.06 | +127% | Bullish | |
| $1.14 | $1.53 | $2.23 | +143% | Bullish | |
| $1.10 | $1.49 | $2.19 | +137% | Bullish | |
| $1.75 | $2.49 | $3.85 | +296% | Bullish | |
| $2.76 | $4.24 | $7.02 | +572% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.554 | $0.63 | $0.7653 | +0.00% |
| August 2026 | $0.5551 | $0.6504 | $0.7791 | +3.24% |
| September 2026 | $0.5593 | $0.6586 | $0.7953 | +1.27% |
| October 2026 | $0.5774 | $0.6829 | $0.8303 | +3.69% |
| November 2026 | $0.5805 | $0.689 | $0.8425 | +0.89% |
| December 2026 | $0.5707 | $0.6797 | $0.8356 | -1.34% |
Click any year to see its month-by-month VYNE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, VYNE could reach as high as $0.8356, with a base case around $0.63 and support toward $0.554 — roughly 0% from $0.63. A consolidation phase looks the most probable path here.
Expect VYNE to range from $0.6014 to $0.9444 through 2027. The $0.7366 average target implies a +17% move from current prices. That is up +17% on the projected 2026 average. Price action looks broadly range-bound.
The VYNE price prediction for 2028 points to an average of $0.8418 (low $0.6741, high $1.11) — a potential gain of +34% on today's $0.63. Buyers look set to stay in control over this stretch.
In 2029, VYNE is projected to trade between $0.6855 and $1.17, averaging $0.8699 — a potential gain of +38% from today's $0.63. That is up +3% on the projected 2028 average. Momentum favours further upside here.
VYNE Therapeutics Inc.'s 2030 outlook centres on $0.9064, within a $0.7042 to $1.24 range. That is up +4% on the projected 2029 average. That marks a +44% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, VYNE could reach as high as $1.52, with a base case around $1.09 and support toward $0.835 — roughly +73% from $0.63. Momentum favours further upside here.
Expect VYNE to range from $0.9543 to $1.78 through 2032. The $1.26 average target implies a +100% move from current prices. That is up +16% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The VYNE price prediction for 2033 points to an average of $1.43 (low $1.07, high $2.06) — a potential gain of +127% on today's $0.63. Momentum favours further upside here.
In 2034, VYNE is projected to trade between $1.14 and $2.23, averaging $1.53 — a potential gain of +143% from today's $0.63. That is up +7% on the projected 2033 average. Buyers look set to stay in control over this stretch.
VYNE Therapeutics Inc.'s 2035 outlook centres on $1.49, within a $1.10 to $2.19 range. That is -3% versus the projected 2034 average. That marks a +137% change versus current levels. Momentum favours further upside here.
By 2040, VYNE could reach as high as $3.85, with a base case around $2.49 and support toward $1.75 — roughly +296% from $0.63. Buyers look set to stay in control over this stretch.
Expect VYNE to range from $2.76 to $7.02 through 2050. The $4.24 average target implies a +572% move from current prices. That is up +70% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in VYNE today (≈ 1,587.301587 VYNE) could be worth
$6,724.42
+$5,724.42 (+572%) by 2050 · US Dollar
Based on the average projected VYNE price of $4.24 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VYNEwould be worth at today's price.
$1,000 invested in VYNE on Jul 10, 2025 (≈ 724.637684 VYNE) would be worth
$456.52
-$543.48 (-54.3%) today · 0.46× · US Dollar
Based on a VYNE entry price of $1.38 vs. today's $0.63.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.68 | $926.47 | -7.4% |
| 1 month ago | $0.659 | $955.99 | -4.4% |
| 3 months ago | $0.61 | $1,032.79 | +3.3% |
| 6 months ago | $0.56 | $1,125 | +12.5% |
| 1 year ago | $1.38 | $456.52 | -54.3% |
| All time (5.0y) ago | $54.54 | $11.55 | -98.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VYNE forecast.
Our base-case forecast reaches $1.30 around 2033.
Implied market cap at $1.30: $43.4M
The multi-year forecast shows a bullish trajectory with a rising average price and sizable upside through 2050. In 2026 the average is $0.63, then 2027 $0.7366 and 2028 $0.8418, with the 2029 average at $0.8699 and 2030 at $0.9064. The corresponding max prices for those years are $0.8356 (2026), $0.9444 (2027), $1.11 (2028), $1.17 (2029), and $1.24 (2030).
By 2031–2035 the averages trend higher toward $1.09, $1.26, $1.43, $1.53, and $1.49 respectively, with 2031–2035 max values reaching $1.52, $1.78, $2.06, $2.23, and $2.19.
Longer-range targets show substantial upside, with 2040 averaging $2.49 and a max of $3.85, and 2050 averaging $4.24 with a max of $7.02. Corresponding ROI figures climb from 0 (2026) to 16.9 (2027), 33.6 (2028), 38.1 (2029), 43.9 (2030), 72.8 (2031), 99.8 (2032), 127.3 (2033), 143.4 (2034), 137.1 (2035), 295.8 (2040), and 572.4 (2050). The sentiment is bullish from 2027 onward, with the longer horizon showing the strongest upside potential, though these are estimates and not guarantees.
Tap a question to reveal the answer.
2030 avg $0.9064; max $1.24; ROI 43.9; sentiment BULLISH.
Forecasts show a bullish path with average prices rising to $4.24 by 2050 and max up to $7.02, with ROI up to 572.4 by 2050; earlier years show neutral to bullish momentum. These are estimates, not guarantees.
Yes. 2034 max $2.23; avg $1.53; min $1.14; ROI 143.4; sentiment BULLISH.
RSI14 is 40; SMA50 is $0.6611; SMA200 is $0.5406. Current price is $0.63 with support at $0.622 and resistance at $0.687. The 30-day range is $0.5532-$0.7175 and annualized volatility is 40%.
Current price $0.63; market cap $21.03M.
VYNE Therapeutics Inc. Community Discussion
0Share your VYNE Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.